1672 — Ascletis Pharma Share News
0.000.00%
Last trade - 00:00- HK$10.63bn
- HK$8.44bn
- CNY2.03m
Brief: Ascletis Announces U.S. IND Approval Of Oral Pd-L1 Small Molecule Inhibitor Asc61 For Treatment Of Advanced Solid Tumors
Brief: Ascletis Announces Ind Filing Of Its Second Fasn Inhibitor Asc60 For Advanced Solid Tumors Accepted By China Nmpa
Brief: Ascletis Pharma Says IND Filing Of Second FASN Inhibitor ASC60 Was Accepted By China NMPA
Brief: Ascletis Pharma Announces Signing Of Ritonavir Tablet Purchase Agreement Between Phokam Pharmaceutical Import-Export Co & Unit
HK's Ascletis Pharma at near 2-year high on FDA's approval for drug application
Brief: Ascletis Pharma Inc Announces IND Approval By U.S. FDA For Development Of Asc22 (Envafolimab)
Brief: Ascletis Says Filing Of U.S. IND For Oral PD-L1 Small Molecule Inhibitor For Treatment Of Advanced Solid Tumors
HK-listed Ascletis Pharma jumps most in 23 months on expanding production capacity
Brief: Ascletis Pharma Expands Ritonavir Oral Tablet Production Capacity To 100 Mln Tablets
Hansoh leads gains among HK-listed drugmakers on China's reimbursement list inclusion
Brief: Ascletis Pharma Announces Inclusion Of Asclevir/Ganovo- Regimen In China's NDRL
Brief: Ascletis Pharma - China Nmpa Approved Phase Ii And Iii Protocols Of Asc42, An Fxr Agonist, For Treatment Of Primary Biliary Cholangitis
Brief: Ascletis Pharma Announces Approval Of Phase II Clinical Trial Of Asc22 By China NMPA
Brief: Ascletis Pharma Announces Exclusive And Worldwide License Agreement Outside Greater China With Suzhou Alphamab
Brief: Ascletis Pharma Announces U.S. Ind Approval Of Asc43f
HK-listed Ascletis Pharma jumps most in over 4 months on share buyback plan
Brief: Ascletis Pharma Says Clinical Trial Application Of Asc42 Accepted For Review By China NMPA
Brief: Ascletis Pharma Posts HY Loss Attributable RMB110.8 Mln Vs Loss Of RMB51.5 Mln
Brief: Ascletis Pharma Says NMPA Approves Phase II Clinical Trial Of Asc40 For Treatment Of Acne